首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Blood Cancer Journal

Blood Cancer Journal杂志,由Springer Nature出版,于2011年创刊,1 issue/year,出版语言English,ISSN:2044-5385,E-ISSN:2044-5385。

投稿咨询
Blood Cancer Journal
Blood Cancer Journal
Blood Cancer Journal
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
13.8
CiteScore
16.2
期刊收录
SCI、SCIE

Blood Cancer Journal(中文译名:《血癌杂志》),ISSN:2044-5385,EISSN:2044-5385,是Springer Nature出版的国际性学术期刊,创刊于2011年,以1 issue/year形式稳定发行,2026年总发文量约105篇。该刊采用OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达13.8,2025年期刊CiteScore为16.2,2025年期刊自引率约3.6%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Blood Cancer Journal长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期>12周,或约稿,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAItaly、GERMANY (FED REP GER)、France、Spain、England、CHINA MAINLAND等为核心发文国家与地区;MAYO CLINICHARVARD UNIVERSITY、UNIVERSITY OF TEXAS SYSTEM、HELMHOLTZ ASSOCIATION、RUPRECHT KARLS UNIVERSITY HEIDELBERG、UNIVERSITY OF FLORENCE、NATIONAL & KAPODISTRIAN UNIVERSITY OF ATHENS等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学 HEMATOLOGY 血液学
1区 1区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
1区 1区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
1区 1区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 6 / 103

94.7

学科:ONCOLOGY SCIE Q1 24 / 333

92.9

学科:HEMATOLOGY SCIE Q1 7 / 103

93.69

学科:ONCOLOGY SCIE Q1 29 / 333

91.44

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 5 / 97

95.4

学科:ONCOLOGY SCIE Q1 18 / 322

94.6

学科:HEMATOLOGY SCIE Q1 8 / 97

92.27

学科:ONCOLOGY SCIE Q1 28 / 322

91.46


中国学者近期发文

1
Utility of dual assessment of cyTRBC1 and cyTRBC2 by flow cytometry for identifying clonality in sCD3-negative to dimly expressing T cell

Author:Li, Mingyong; Fu, Jun; Li, Yanxin; Fan, Xiaoming; Zhang, Liuyun; Zhou, Lingjie; Zhang, Jin; Zhang, Juan; Xi, Qian

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01483-1

2
Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib stud

Author:Yang, Fan; Liu, Rui; Fu, Zhonghua; Guo, Yuelu; Ma, Lixia; Cao, Miaomiao; Deng, Biping; Chang, Alex H.; Wu, Haifeng; Gan, Shilin; Chen, Chen; Ke, Xiaoyan; Hu, Kai

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01476-0

3
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelom

Author:Kumar, Shaji; Jagannath, Sundar; Weisel, Katja C.; Rosinol, Laura; Leleu, Xavier; Dimopoulos, Meletios-Athanasios; Kastritis, Efstathios; Siegel, David S.; Monge, Jorge; Du, Juan; de la Rubia, Javier; Asensi Canto, Pedro; Lee, Jae Hoon; Mateos, Maria-Victoria; Puertas, Borja; Gozzetti, Alessandro; Dytfeld, Dominik; Ocio, Enrique M.; Blade, Joan; Ozaki, Shuji; Beksac, Meral; Escalante, Fernando; Nagaraj, Madhu; Hassan, Rafla; Bonar, Nicolle; Spin, Paul; Shokoohi, Mostafa; Siddiqui, Muhaimen; Wang, Di; Hou, Kevin; West, Michael E. D.; Hampp, Christian; Green, Jeannette; Humblet, Olivier; Breskin, Alexander; Harnett, James; Ge, Wenzhen; Sobel, Rachel E.; Jalbert, Jessica J.; Kroog, Glenn S.; Rodriguez Lorenc, Karen; Ma, Qiufei; Durie, Brian G. M

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01466-2

4
Efficacy and safety of short-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemi

Author:Liu, Ge; Zhou, Yile; Lou, Yinjun; Ai, Hao; Mao, Liping; Wang, Qian; Wu, Hongfei; Tong, Hongyan; Wei, Xudong; Jin, Jie; Wang, Huafeng; Yin, Qingsong

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01460-8

5
Imatinib and nilotinib are equally successful in achieving therapy-free remissio

Author:Cheng, Fang; Wang, Yu; Yang, Yunfan; Du, Xin; Zhu, Yu; Weng, Jianyu; Xu, Na; Huang, Jian; Liu, Zhenfang; Ren, Hongbo; Zhao, Huifang; Zhu, Huanling; Jiang, Qian; Zhang, Yanli; Li, Weiming

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01462-6

6
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26

Author:Wei, Juying; Cai, Qingqing; Zhang, Liling; Zou, Liqun; Li, Zengjun; Zhou, Keshu; Wu, Huijing; Qiu, Lihua; Su, Liping; Ding, Kaiyang; Zhou, Hui; Yu, Li; Li, Fei; Li, Wenyu; Lin, Li'e; Xiao, Qing; Wang, Erhua; Jing, Hongmei; Zheng, Meifang; Zhang, Hongyu; Gao, Yuhuan; Gao, Da; Chen, Lijia; Jin, Jie

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01452-8

7
Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort stud

Author:Zou, Qihua; Cao, Yi; Wang, Liang; Li, Wuping; Yin, Qingsong; Wu, Yudan; Jing, Hongmei; Peng, Zhigang; Sun, Xiuhua; Rao, Jun; Chen, Ying; Zhang, Hongyu; Zeng, Dongfeng; Li, Bingzong; Zhao, Ying; Zhang, Xudong; Zhang, Yuchen; Gao, Yan; Bai, Bing; Xia, Yi; Fang, Yu; Chen, Zouxiang; Nie, Man; Fang, Xiaojie; Bai, Shenrui; Huang, Huiqiang; Cai, Qingqing; Cai, Jun

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01459-1

8
Long-term outcomes of autologous stem cell transplantation for AL amyloidosis: a 15-year experience from a Chinese referral center and a comparison of different era

Author:Liu, Mengnan; Guo, Jinzhou; Chen, Wencui; Wu, Xiaomei; Xu, Weiwei; Huang, Xianghua

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01464-4

9
Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancie

Author:Li, Tingting; Wang, Chaoyu; Xiao, Qing; Zhang, Xiaomei; Yang, Zailin; Li, Jun; Liu, Yao

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01453-7

10
Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 tria

Author:Shen, Hao-Rui; Wu, Jia-Zhu; Yin, Hua; Du, Kai-Xin; Sibusiso, Luthuli; Wu, Yi-Fan; Hua, Wei; Li, Yue; Kong, Yi-Lin; Zhang, Xin-Yu; Gao, Rui; Li, Jian-Yong; Wang, Li; Liang, Jin-Hua; Xu, Wei

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01450-w


在线咨询

Blood Cancer Journal

国际简称:BLOOD CANCER J参考译名:血癌杂志

年发文量:105 CiteScore:16.2 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:92.38%

杂志社联系方式:CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW

Blood Cancer Journal